首页|美托洛尔联合厄贝沙坦治疗老年高血压的临床效果探讨

美托洛尔联合厄贝沙坦治疗老年高血压的临床效果探讨

扫码查看
目的 探讨美托洛尔联合厄贝沙坦治疗老年高血压的临床效果。方法 120例老年高血压患者,随机分为二联降压组和单一降压组,每组 60 例。单一降压组应用厄贝沙坦治疗,二联降压组在单一降压组基础上增加美托洛尔治疗。比较两组血压水平、血压达标率、生活质量评分、不良反应发生率。结果 二联降压组治疗 1、2、3 个月后收缩压(140。03±14。25)、(135。71±15。72)、(133。24±12。02)mm Hg(1 mm Hg=0。133 kPa)和舒张压(86。25±5。37)、(84。69±4。52)、(82。36±5。62)mm Hg显著低于单一降压组的(150。71±13。85)、(145。02±14。13)、(138。52±14。78)mm Hg 和(91。39±6。87)、(87。25±5。37)、(85。19±4。98)mm Hg(P<0。05)。二联降压组治疗 1、2、3 个月后血压达标率分别为 63。33%、76。67%、93。33%,均显著高于单一降压组的 41。67%、58。33%、78。33%(P<0。05)。二联降压组治疗后健康调查简表(SF-36)中生理功能、情感职能、生理职能、社会功能、精神健康、精力评分及总分均显著高于单一降压组(P<0。05)。二联降压组不良反应发生率11。67%(7/60)与单一降压组的8。33%(5/60)比较,差异无统计学意义(P>0。05)。结论 在厄贝沙坦降压治疗基础上联合美托洛尔协同治疗,可有效降低老年高血压患者的血压水平,提高血压达标率、生活质量,安全性高,预后良好。
Clinical efficacy of metoprolol combined with irbesartan in the treatment of hypertension in the elderly
Objective To explore the clinical effect of metoprolol combined with irbesartan in the treatment of hypertension in the elderly.Methods 120 elderly patients with hypertension were randomly divided into a dual antihypertensive group and a single antihypertensive group,with 60 patients in each group.The single antihypertensive group was treated with irbesartan,and the dual antihypertensive group was treated with metoprolol on the basis of the single antihypertensive group.The blood pressure level,blood pressure compliance rate,quality of life score and incidence of adverse reactions were compared between the two groups.Results After 1,2 and 3 months of treatment,the systolic blood pressure of the dual antihypertensive group were(140.03±14.25),(135.71±15.72),(133.24±12.02)mm Hg(1 mm Hg=0.133 kPa),and the diastolic blood pressure were(86.25±5.37),(84.69±4.52),(82.36±5.62)mm Hg,which were significantly lower than(150.71±13.85),(145.02±14.13),(138.52±14.78)mm Hg and(91.39±6.87),(87.25±5.37),(85.19±4.98)mm Hg in the single antihypertensive group(P<0.05).After 1,2 and 3 months of treatment,the blood pressure compliance rate of the dual antihypertensive group were 63.33%,76.67%and 93.33%,which were significantly higher than 41.67%,58.33%and 78.33%of the single antihypertensive group(P<0.05).After treatment,the scores of physical function,role-emotional,physical function,social function,mental health,energy and total score in 36-item short-form health survey(SF-36)in the dual antihypertensive group were significantly higher than those in the single antihypertensive group(P<0.05).There was no significant difference in the incidence of adverse reactions between the dual antihypertensive group and the single antihypertensive group[11.67%(7/60)vs 8.33%(5/60)](P>0.05).Conclusion Combined treatment with metoprolol on the basis of irbesartan antihypertensive therapy can effectively reduce the blood pressure level in elderly patients with hypertension,improve the blood pressure compliance rate,quality of life,and it has high safety and good prognosis.

HypertensionOld ageIrbesartanMetoprololClinical effectsMedication safety

金勇、李艳

展开 >

100030 北京市第二医院急诊科

100030 北京市第二医院综合内科

高血压 老年 厄贝沙坦 美托洛尔 临床效果 用药安全性

2024

中国现代药物应用
中国水利电力医学科学技术学会

中国现代药物应用

影响因子:0.862
ISSN:1673-9523
年,卷(期):2024.18(9)